Merck
Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events
Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations
Evaluation of Keytruda Combined with Chemotherapy as Post-Surgical Treatment in Newly Diagnosed Endometrial Cancer Shows Limited Efficacy
Keytruda, Merck, endometrial cancer, post-surgical therapy, newly diagnosed, chemotherapy, clinical trial, limited efficacy.
Pharma Executives of BMS, J&J, and Merck Confronted in Senate Hearing on Sky-High Drug Prices
United States, Prices, CEOs, Country, Johnson and Johnson, R&D, Merck